Why the study?
Do age and sex affect the single-dose pharmacokinetics and pharmacodynamics of apixaban?
Do age and sex affect the single-dose pharmacokinetics and pharmacodynamics of apixaban?
Apixaban dosing does not need to be adjusted based on age or sex alone.
Answers are grounded in this paper and cite their sources.
Supports current apixaban dosing without age- or sex-based adjustments; leaves open validation in broader populations.
There were no clinically meaningful age- or sex-related differences in the pharmacokinetics and pharmacodynamics of apixaban that would require dose modification on the basis of age or sex alone.
No takes yet. Share an insight, caveat, or question.
Frost et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: